Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia in Children
Interventions
OTHER

Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test

"1. Leukemia cells from newly diagnosed and relapsed children with AML were tested for high throughput in vitro drug sensitivity and resistance.~2. Combined with multi-omics sequencing technology such as whole exome and transcriptome, the data of drug sensitivity, drug resistance and genomic characteristics of children AML patients were integrated, and the internal rules between drug sensitivity or drug resistance and molecular characteristics such as gene fusion, gene mutation and abnormal gene expression of children AML patients were deeply analyzed, and the molecular characteristics of drug sensitivity in children AML were mapped"

Trial Locations (1)

310000

RECRUITING

Children's Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

College of Pharmaceutical Science at Zhejiang University

UNKNOWN

lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER